Despite different tissue distribution and physiological effects, the three isoforms (PPAR-α, PPAR-β/δ, and PPAR-γ) commonly play critical roles in the regulation of lipid and glucose metabolism [111], which could benefit the treatment of NAFLD [112]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.